A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-Label Phase I Part to Assess the Safety and Tolerability of AZD2171 in Combination With FOLFOX Followed by a Phase II, Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy of AZD2171 in Combination With FOLFOX

ABSTRACT: Intervention name : AZD2171 Dosage And administration of the intervention : Oral Primary outcome(s): Efficacy Primary Outcome Measures:- Progression of Metastatic Colorectal Cancer (mCRC) - PFS Secondary Outcome Measures: - Safety and tolerability [Time Frame: assessed at each visit] Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment Study

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2610037 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR